• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超声引导下微波消融治疗 MEN1 患者复发性原发性甲状旁腺功能亢进症 1 例报告。

Ultrasound-guided microwave ablation in the treatment of recurrent primary hyperparathyroidism in a patient with MEN1: a case report.

机构信息

Endocrine and Diabetes Center, The Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China.

Department of Ultrasound, The Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China.

出版信息

Front Endocrinol (Lausanne). 2023 Sep 19;14:1175377. doi: 10.3389/fendo.2023.1175377. eCollection 2023.

DOI:10.3389/fendo.2023.1175377
PMID:37795364
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10546301/
Abstract

BACKGROUND

Multiple endocrine neoplasia type 1 (MEN1) is an inherited endocrine syndrome caused by the mutation in the tumor suppressor gene . The recurrence rate of primary hyperparathyroidism (PHPT) in patients with MEN1 after parathyroidectomy remains high, and the management of recurrent hyperparathyroidism is still challenging.

CASE PRESENTATION

We reported a 44-year-old woman with MEN1 combined with PHPT who was diagnosed through genetic screening of the patient and her family members. After parathyroidectomy to remove one parathyroid gland, the patient suffered from persistent high levels of serum calcium and parathyroid hormone, which returned to normal at up to 8 months after ultrasound-guided microwave ablation (MWA) for bilateral parathyroid glands, suggesting an acceptable short-term prognosis.

CONCLUSION

Ultrasound-guided MWA for parathyroid nodules may be an effective therapeutic strategy for recurrent PHPT in MEN1 patients.

摘要

背景

多发性内分泌腺瘤病 1 型(MEN1)是一种由肿瘤抑制基因 突变引起的遗传性内分泌综合征。MEN1 患者甲状旁腺切除术后原发性甲状旁腺功能亢进症(PHPT)的复发率仍然很高,复发性甲状旁腺功能亢进症的管理仍然具有挑战性。

病例介绍

我们报告了一例 44 岁的 MEN1 合并 PHPT 女性患者,该患者通过对患者及其家庭成员进行基因筛查而确诊。甲状旁腺切除术后切除了一个甲状旁腺,患者的血清钙和甲状旁腺激素持续升高,在双侧甲状旁腺超声引导微波消融(MWA)后长达 8 个月才恢复正常,提示短期预后尚可。

结论

超声引导 MWA 治疗甲状旁腺结节可能是 MEN1 患者复发性 PHPT 的有效治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/26800a33c4d2/fendo-14-1175377-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/edb0f12971da/fendo-14-1175377-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/ec158ab8c171/fendo-14-1175377-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/63a8afb1e871/fendo-14-1175377-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/26800a33c4d2/fendo-14-1175377-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/edb0f12971da/fendo-14-1175377-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/ec158ab8c171/fendo-14-1175377-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/63a8afb1e871/fendo-14-1175377-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bb8/10546301/26800a33c4d2/fendo-14-1175377-g004.jpg

相似文献

1
Ultrasound-guided microwave ablation in the treatment of recurrent primary hyperparathyroidism in a patient with MEN1: a case report.超声引导下微波消融治疗 MEN1 患者复发性原发性甲状旁腺功能亢进症 1 例报告。
Front Endocrinol (Lausanne). 2023 Sep 19;14:1175377. doi: 10.3389/fendo.2023.1175377. eCollection 2023.
2
Microwave ablation for recurrent primary hyperparathyroidism in four patients with multiple endocrine neoplasia type 1: a case series report.微波消融治疗多发性内分泌腺瘤病 1 型 4 例复发性甲状旁腺功能亢进症:病例系列报告。
Int J Hyperthermia. 2024;41(1):2308056. doi: 10.1080/02656736.2024.2308056. Epub 2024 Feb 5.
3
Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism.1型多发性内分泌腺瘤病相关原发性甲状旁腺功能亢进患者的再次手术
Ann Surg Oncol. 2016 Dec;23(Suppl 5):701-707. doi: 10.1245/s10434-016-5467-x. Epub 2016 Jul 27.
4
Cystic parathyroid glands in MEN1: A rare entity?多发性内分泌腺瘤1型中的甲状旁腺囊肿:一种罕见的实体?
Fam Cancer. 2017 Apr;16(2):249-256. doi: 10.1007/s10689-016-9936-y.
5
Bone Turnover Markers in Response to Ultrasound-Guided Microwave Ablation for Primary Hyperparathyroidism.原发性甲状旁腺功能亢进症超声引导微波消融治疗后骨转换标志物的变化
Front Endocrinol (Lausanne). 2021 Dec 1;12:782050. doi: 10.3389/fendo.2021.782050. eCollection 2021.
6
Safety and efficacy of percutaneous parathyroid ethanol ablation in patients with recurrent primary hyperparathyroidism and multiple endocrine neoplasia type 1.经皮甲状旁腺乙醇消融术治疗复发性原发性甲状旁腺功能亢进症和1型多发性内分泌腺瘤病患者的安全性和有效性。
J Clin Endocrinol Metab. 2015 Jan;100(1):E87-90. doi: 10.1210/jc.2014-3255.
7
Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.盐酸西那卡塞在1型多发性内分泌腺瘤病原发性甲状旁腺功能亢进临床管理中的作用
Minerva Endocrinol. 2013 Dec;38(4):389-94.
8
Recurrence After Surgery for Primary Hyperparathyroidism in 517 Patients With Multiple Endocrine Neoplasia Type 1: An Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines study.517例1型多发性内分泌腺瘤病患者原发性甲状旁腺功能亢进手术后的复发情况:法语国家内分泌外科学会和内分泌肿瘤研究小组的一项研究
Ann Surg. 2024 Feb 1;279(2):340-345. doi: 10.1097/SLA.0000000000005980. Epub 2023 Jul 3.
9
Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure.1型多发性内分泌腺瘤病相关原发性甲状旁腺功能亢进的局限性甲状旁腺切除术:失败的根源。
Ann Surg Oncol. 2016 Feb;23(2):416-23. doi: 10.1245/s10434-015-4865-9. Epub 2015 Nov 5.
10
Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1.特定1型多发性内分泌腺瘤病患者原发性甲状旁腺功能亢进症的单侧清除术
World J Surg. 2016 Dec;40(12):2964-2969. doi: 10.1007/s00268-016-3624-9.

本文引用的文献

1
Ultrasound-Guided Radiofrequency Ablation for Primary Hyperparathyroidism Induced by Multiple Endocrine Neoplasia 1-A Case Report.超声引导下射频消融治疗多内分泌腺瘤病1型所致原发性甲状旁腺功能亢进——病例报告
Diagnostics (Basel). 2022 Oct 20;12(10):2553. doi: 10.3390/diagnostics12102553.
2
Update on the clinical management of multiple endocrine neoplasia type 1.1 型多发性内分泌肿瘤的临床管理进展。
Clin Endocrinol (Oxf). 2022 Oct;97(4):409-423. doi: 10.1111/cen.14727. Epub 2022 Apr 1.
3
Bone Turnover Markers in Response to Ultrasound-Guided Microwave Ablation for Primary Hyperparathyroidism.
原发性甲状旁腺功能亢进症超声引导微波消融治疗后骨转换标志物的变化
Front Endocrinol (Lausanne). 2021 Dec 1;12:782050. doi: 10.3389/fendo.2021.782050. eCollection 2021.
4
Effectiveness and Safety of Thermal Ablation in the Treatment of Primary Hyperparathyroidism: A Multicenter Study.热消融治疗原发性甲状旁腺功能亢进症的有效性和安全性:一项多中心研究。
J Clin Endocrinol Metab. 2021 Aug 18;106(9):2707-2717. doi: 10.1210/clinem/dgab240.
5
Ultrasound-guided ethanol injection for the treatment of parathyroid adenoma: A prospective self-controlled study.超声引导下乙醇注射治疗甲状旁腺腺瘤:一项前瞻性自身对照研究。
J Res Med Sci. 2020 Oct 28;25:93. doi: 10.4103/jrms.JRMS_553_19. eCollection 2020.
6
Optimal extent of initial parathyroid resection in patients with multiple endocrine neoplasia syndrome type 1: A meta-analysis.1 型多发性内分泌肿瘤综合征患者初始甲状旁腺切除术的最佳范围:一项荟萃分析。
Surgery. 2021 Feb;169(2):302-310. doi: 10.1016/j.surg.2020.08.021. Epub 2020 Sep 30.
7
Benefit of diverse surgical approach on short-term outcomes of MEN1-related hyperparathyroidism.不同手术入路对 MEN1 相关甲状旁腺功能亢进症短期结局的影响。
Sci Rep. 2020 Jun 30;10(1):10634. doi: 10.1038/s41598-020-67424-5.
8
Clinical Study on Safety and Efficacy of Microwave Ablation for Primary Hyperparathyroidism.微波消融治疗原发性甲状旁腺功能亢进症的安全性和有效性的临床研究。
Korean J Radiol. 2020 May;21(5):572-581. doi: 10.3348/kjr.2019.0593.
9
Single gland excision for MEN1-associated primary hyperparathyroidism.单侧腺叶切除术治疗 MEN1 相关性原发性甲状旁腺功能亢进症。
Clin Endocrinol (Oxf). 2020 Jan;92(1):63-70. doi: 10.1111/cen.14112. Epub 2019 Nov 12.
10
Comparison of ultrasound-guided percutaneous microwave ablation and parathyroidectomy for primary hyperparathyroidism.超声引导下经皮微波消融与甲状旁腺切除术治疗原发性甲状旁腺功能亢进症的比较。
Int J Hyperthermia. 2019;36(1):835-840. doi: 10.1080/02656736.2019.1645365.